Literature DB >> 20397922

PET and PET-CT in radiation treatment planning for lung cancer.

Cynthia Aristei1, Lorenzo Falcinelli, Barbara Palumbo, Roberto Tarducci.   

Abstract

This review analyzes PET images in radiotherapy treatment planning for lung cancer patients and discusses the most controversial current issues. Computed tomography images are commonly used to assess location and extension of target volumes and organs at risk in radiotherapy treatment planning. Although PET is more sensitive and specific, contouring on PET images is difficult because tumor margins are indistinct, due to heterogeneous (18)fluorodeoxyglucose uptake distribution and limited spatial resolution. The best target delineation criteria have not yet been established. In non-small-cell lung cancer, PET appears to improve sparing of organs at risk and reduce the risk of toxicity; prescribed doses can be increased. Data are scarce on small-cell lung cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20397922     DOI: 10.1586/era.09.195

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

Review 1.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

2.  Metabolic Tumor Volume on PET Reduced More than Gross Tumor Volume on CT during Radiotherapy in Patients with Non-Small Cell Lung Cancer Treated with 3DCRT or SBRT.

Authors:  Pawinee Mahasittiwat; Shuanghu Yuan; Congying Xie; Timothy Ritter; Yue Cao; Randall K Ten Haken; Feng-Ming Spring Kong
Journal:  J Radiat Oncol       Date:  2013-06

3.  Implementation of diffusion-weighted magnetic resonance imaging in target delineation of central lung cancer accompanied with atelectasis in precision radiotherapy.

Authors:  Xinli Zhang; Zheng Fu; Guanzhong Gong; Hong Wei; Jinghao Duan; Zhaoqiu Chen; Xiangming Chen; Ruozheng Wang; Yong Yin
Journal:  Oncol Lett       Date:  2017-06-23       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.